Article
Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
BMC pulmonary medicine - 1 Jul 2021
Qu Ge-Ping, Shi Min, Wang Dan, Wu Jiong-He, Wang Peng, Gong Mei-Liang, Zhang Zhi-Jian
Abstract excerpt
BACKGROUND: Molecular targeted therapy for non-small cell lung carcinoma (NSCLC) is restricted due to resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This study evaluated the effects of dual targeting of MEK and PI3K in human EGFR-TKI resistant NSCLC cell lines. METHODS: EGFR-TKI resistant NSCLC cell lines H1975, H460, and A549, with different mutation and amplification...
Topics
- Afatinib
- Aminopyridines
- Antineoplastic Combined Chemotherapy Protocols
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Cell Proliferation
- Drug Resistance, Neoplasm
- ErbB Receptors
- Humans
- Lung Neoplasms
- Mitogen-Activated Protein Kinase Kinases